… Colhoun has received honoraria grants through the EU Innovative Medicines Initiative
from AstraZeneca , Boehringer Ingelheim Ltd. UK , Eli Lilly and Co., Ltd. , JRDF , Pfizer Inc. , …

Inability to replicate many results has led to increasing scepticism about the value of simple
association study designs for detection of genetic variants contributing to common complex …

Background: Mortality rates from hypertension related diseases such as coronary heart
disease, hypertensive heart disease, stroke and end stage renal disease show an inverse …

Background Type 2 diabetes is associated with a substantially increased risk of cardiovascular
disease, but the role of lipid-lowering therapy with statins for the primary prevention of …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …

… Dr Colhoun reports receipt of research grant support through the EU Innovative Medicines
Initiative from Roche, Pfizer, Eli Lilly, Boehringer-Ingelheim, sanofi-aventis, and AstraZeneca; …

… Dr Colhoun reported receiving grants, personal fees, and costs for advisory panel participation
from Pfizer Inc; costs for advisory panel and contribution to sponsored clinical trial from …

Effect of Vaccination on Transmission of SARS-CoV-2 | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Background We aimed to ascertain the cumulative risk of fatal or critical care unit-treated
COVID-19 in people with diabetes and compare it with that of people without diabetes, and to …